Now showing items 1-5 of 5

    • Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. 

      Little, SE; Bax, DA; Rodriguez-Pinilla, M; Natrajan, R; Messahel, B; Pritchard-Jones, K; Vujanic, GM; Reis-Filho, JS; Jones, C (2007-08)
      PURPOSE: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase overexpressed in a variety of human malignancies, against which targeted therapies have shown efficacy in lung and brain tumors. Clinical ...
    • PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. 

      Gupta, A; Anjomani-Virmouni, S; Koundouros, N; Dimitriadi, M; Choo-Wing, R; Valle, A; Zheng, Y; Chiu, Y-H; Agnihotri, S; Zadeh, G; Asara, JM; Anastasiou, D; Arends, MJ; Cantley, LC; Poulogiannis, G (2017-03-16)
      PARK2 is a gene implicated in disease states with opposing responses in cell fate determination, yet its contribution in pro-survival signaling is largely unknown. Here we show that PARK2 is altered in over a third of all ...
    • Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. 

      Dreyling, M; Morschhauser, F; Bouabdallah, K; Bron, D; Cunningham, D; Assouline, SE; Verhoef, G; Linton, K; Thieblemont, C; Vitolo, U; Hiemeyer, F; Giurescu, M; Garcia-Vargas, J; Gorbatchevsky, I; Liu, L; Koechert, K; Peña, C; Neves, M; Childs, BH; Zinzani, PL (2017-09-01)
      Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib ...
    • Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. 

      Wilkerson, PM; Dedes, KJ; Samartzis, EP; Dedes, I; Lambros, MB; Natrajan, R; Gauthier, A; Piscuoglio, S; Töpfer, C; Vukovic, V; Daley, F; Weigelt, B; Reis-Filho, JS (2017-01-24)
      PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. ...
    • Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. 

      Mathew, G; Hannan, A; Hertzler-Schaefer, K; Wang, F; Feng, G-S; Zhong, J; Zhao, JJ; Downward, J; Zhang, X (2016-11-15)
      Deficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified ...